If you need more lookups,
subscriptions start at $34 USD/month.
Matthew Everly Location
Los Angeles, CA, US
Matthew Everly Work
Director, Medical Evidence Generation, Neurology @ (September 2025 - Present)
Senior Director, Global Portfolio Strategy and Evidence Generation @ (December 2022 - August 2025)
Senior Global Evidence Generation and Solutions Director @ (May 2021 - December 2022)
Director Global Evidence and Outcomes @ (July 2020 - May 2021)
Founder and Principal @ Cleverly Health LLC (April 2020 - April 2021)
Adjunct Associate Professor of Medicine @ (July 2019 - November 2020)
Adjunct Assistant Professor of Medicine @ (May 2012 - July 2019)
Institute Director (chief executive) @ Terasaki Research Institute (August 2014 - April 2020)
Senior Research Scientist (Terasaki Foundation Laboratory) @ Terasaki Research Institute (September 2012 - August 2014)
Chief Scientific Officer @ (November 2009 - September 2012)
Research Scientist (Terasaki Foundation Laboratory) @ Terasaki Research Institute (August 2008 - October 2009)
Pharmacy Clinical Coordinator (Head of Pharmacy Clinical Services) @ (June 2005 - December 2006)
Clinical Pharmacist @ (June 2004 - May 2005)
Matthew Everly Education
University of Cincinnati
Fellowship (Clinical Research)
2008-2008
University of Cincinnati
Residency (Transplant Pharmacy)
2007-2007
University of Cincinnati James L. Winkle College of Pharmacy
Doctor of Pharmacy - PharmD (Pharmacy)
2001-2003
University of Cincinnati James L. Winkle College of Pharmacy
Bachelor of Pharmacy - BPharm
1997-2002
Matthew Everly Summary
Matthew Everly, based in Los Angeles, CA, US, is currently a Director, Medical Evidence Generation, Neurology at Ionis Pharmaceuticals, Inc.. Matthew Everly brings experience from previous roles at Hansa Biopharma, Takeda Oncology and Cleverly Health LLC. Matthew Everly holds a 2008 - 2008 Fellowship in Clinical Research @ University of Cincinnati. Matthew Everly has 2 emails and 3 mobile phone numbers on RocketReach.
Looking for a different Matthew Everly?
Find contact details for 700 million professionals.